« Back to Record
Citation APA

Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortes, J., Hyman, D. D., Juric, D., Krop, I., Bieche, I., Saura, C., Sotiriou, C., Cardoso, F., Loibl, S., Andre, F., & Turner, N. C. (2019). Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of oncology, 30(3), 365-373. doi:10.1093/annonc/mdz036


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/287352

Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortes, J., Hyman, D. D., Juric, D., Krop, I., Bieche, I., Saura, C., Sotiriou, C., Cardoso, F., Loibl, S., Andre, F., & Turner, N. C. (2019). Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of oncology, 30(3), 365-373. doi:10.1093/annonc/mdz036